FIELD: chemistry.
SUBSTANCE: microorganism, which codes antigens and protein toxins, contains a first component, which is at least one nucleotide sequence coding at least at least one complete or partial antigen of at least one wild-type or mutated protein, a second component which is at least one nucleotide sequence coding for at least one protein toxin and/or at least one protein toxin subunit, a third component consisting of at least a first subcomponent which is at least one nucleotide sequence coding at least one transport system which enables the expression of the first and second components on the outer surface of the microorganism and/or enables the secretion of the expression products of the first and second components, and/or coding at least one signal sequence which enables the secretion of the expression products of the first and second components, and/or optionally, from the second subcomponent, which is at least one nucleotide sequence coding at least one protein for lysing the microorganism in the cytosol of mammalian cells and for intracellularly releasing plasmids or expression vectors, which are contained in the lysed microorganism; and a fourth component which is at least one nucleotide sequence for at least one activation sequence for the expression of one or more of the first, second and third components, wherein said activation sequence can be activated in the microorganism and/or is tissue cell-specific, tumour cell-specific, macrophage-specific, dendrite-specific, lymphocyte-specific, function-specific or non-cell-specific, wherein any of the first, second, third or fourth components, present in the microorganism more than once, are independently identical or different, wherein the first and second components are different from each other. Also disclosed are a medicinal agent for stimulating immune response and a pharmaceutical composition based on said microorganism, methods of obtaining said microorganism, the corresponding expression plasmid and expression vector for obtaining said microorganism.
EFFECT: invention enables to obtain novel antitumour vaccines, which induce a strong systemic cellular immune system response, which increases effectiveness of antitumour therapy.
21 cl, 22 dwg, 8 ex
Title | Year | Author | Number |
---|---|---|---|
MICROORGANISMS AS CARRIERS OF NUCLEOTIDE SEQUENCES ENCODING CELLULAR ANTIGENS FOR TREATMENT OF TUMORS | 2003 |
|
RU2319741C2 |
HYBRID PROTEIN VACCINE AGAINST PNEUMONIA CAUSED BY Streptococcus pneumoniae | 2012 |
|
RU2510281C2 |
RECOMBINANT PROTEIN FOR CHOLERA IMMUNIZATION | 2019 |
|
RU2723705C1 |
RECOMBINANT STRAIN MYCOBACTERIUM BOVIS rBCG-1 BASED ON VACCINE STRAIN MYCOBACTERIUM BOVIS BCG STRAIN RUSSIA 368 | 2022 |
|
RU2807732C1 |
FUSED PROTEINS OF CARCINOEMBRYONAL ANTIGEN | 2005 |
|
RU2380375C2 |
METHOD OF INDUCTION OF PROTECTIVE IMMUNE RESPONSE IN MAMMALS TO HELICOBACTER INFECTION, VACCINE FOR INDUCTION OF PROTECTIVE IMMUNE RESPONSE IN MAMMALS FOR HELICOBACTER INFECTION, METHOD OF INDUCTION OF PASSIVE PROTECTION IN MAMMALS AGAINST INFECTION WITH HELICOBACTER, AND METHOD OF ESTIMATION OF ENDOGENOUS IMMUNE RESPONSE IN MAMMALS INFECTED WITH HELICOBACTER | 1993 |
|
RU2125891C1 |
TUBERCULOSIS VACCINE WITH IMPROVED STRENGTH | 2004 |
|
RU2342400C2 |
ENTEROTOXIN MUTANT EFFECTIVE AS NONTOXIC ORAL STIMULATION AGENT | 1995 |
|
RU2160606C2 |
IMMUNOGENIC COMPOSITION AND METHOD OF FUSED PROTEIN VACCINE DEVELOPMENT | 2004 |
|
RU2407749C2 |
ANTIPLAGUE VACCINE | 1996 |
|
RU2197988C2 |
Authors
Dates
2012-04-10—Published
2007-11-13—Filed